Table 3 Significant associations between the plasma levels of exosomal miRNAs and clinicopathological/risk parameters (categorial variables)
Clinical/risk factors | miRNAs* | All BC patients | HER2-positive patients | TNBC patients |
|---|---|---|---|---|
p(t test)** | p(t test)** | p(t test)** | ||
Age (< 50, ≥ 50) | miR-20a | 0.011 | – | – |
miR-30c | – | – | 0.038 | |
miR-99b | 0.006 | – | 0.002 | |
miR-106b | 0.024 | – | – | |
miR-145 | 0.015 | – | 0.040 | |
miR-150 | 0.008 | – | 0.015 | |
miR-185 | 0.035 | – | – | |
miR-202 | 0.046 | – | – | |
miR-301 | 0.019 | 0.032 | – | |
miR-891a | 0.007 | – | 0.010 | |
Nodal status (N0, N+) | miR-16 | – | 0.023 | – |
miR-328 | – | 0.019 | – | |
miR-660 | – | 0.016 | – | |
Tumor size (T1–2, T3–4) | miR-185 | – | 0.040 | – |
miR-199a-3p | 0.034 | – | – | |
miR-374 | – | – | 0.030 | |
miR-376a | – | 0.004 | – | |
miR-382 | 0.031 | 0.014 | – | |
miR-410 | – | 0.038 | – | |
miR-433 | – | 0.037 | – | |
miR-628-5p | – | 0.041 | – | |
Grading (G1–2, G3) | miR-16 | 0.033 | – | – |
miR-20a | 0.024 | – | 0.032 | |
miR-30c | – | – | 0.023 | |
miR-155 | – | – | 0.038 | |
miR-193b | – | – | 0.028 | |
miR-422a | – | 0.010 | – | |
miR-628-5p | – | 0.005 | – | |
Lymphocyte predominant breast cancer (neg, pos) | miR-148a | 0.036 | – | – |
miR-335 | 0.048 | – | – | |
miR-652 | – | 0.040 | – | |
miR-891a | 0.050 | 0.022 | – |